NEUROCRINE BIOSCIENCES INC.
CEO: Kevin Gorman.
Revenue: $77.4 million in 2011; $33.5 million in 2010.
Net income or loss: Net income of $37.6 million in 2011; net loss of $8 million in 2010.
No. of local employees: About 80 full time.
Headquarters: San Diego.
Year founded: 1992.
Stock symbol and exchange: NBIX on Nasdaq.
Company description: Discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders.
Key factors for success: Concentration on building a product portfolio focused on neurological and endocrine-related diseases and disorders; identifying novel drugs to address unmet market opportunities; establishing corporate collaborations with global pharmaceutical companies to assist in the development of products and mitigate financial risk while retaining commercial upside; acquiring rights to complementary drug candidates and technologies.
Diversification is a key ingredient in Neurocrine Biosciences Inc...